The results obtained are summarized as follows: (1) benanomicin A at relatively high concentrations (almost equal to MIC) was fungicidal and disrupted the cell permeability barrier, inducing leakage of intracellular K+and ATPin growing cells, while the antibiotic had none of these effects in non-growing cells; (2) no biosynthesis of any of several major cellular constituents in yeast cells was inhibited markedly or selectively enough to explain its fungitoxic activity; (3) whereas benanomicin A induced lysis ofmetabolically active yeast protoplasts incubated in the presence of glucose, inactive yeast protoplasts incubated without glucose were refractory to the lytic action of the antibiotic; (4) osmotically shocked yeast cells became feasible to the cidal action ofbenanomicin A; (5) benanomicin A substantially inhibited uptake of 6-deoxy-glucose by yeast cells; (6) liposomes composed of phospholipids and cholesterol were not susceptible to benanomicin A; and (7) benanomicin A inhibited in vitro activity of H+-ATPase from yeast cell membranes to a greater extent than that for H+-ATPasefrom yeast mitochondria or H+-ATPasefrom yeast vacuolar membranes.
Based on these and our previous data that benanomicin A preferentially binds to mannan or mannoproteins constituting the cell wall and cell membraneof yeasts, such binding of the antibiotic is suggested to deteriorate the normal structure and function of those cell membranesof yeasts which are in a growing or metabolically active state, ultimately leading to cell death.
Treatment with a polyene amphotericin B and several azoles such as fluconazole is a mainstream of the chemotherapy for systemic fungal infections which has risen dramatically in recent years. However, these drugs have drawbacks associated with their safety in the former and their efficacy in the latter. Thus their clinical usefulness is considerably limited. To overcome this situation, the discovery and development of newclasses of antifungal agents which show low toxicity and high efficacy is urgently required.
Benanomicin Aproduced by Actinomadura sporax is a new class of antifungal agent possessing a benzo-(a)-naphthacenequinone skeleton1 '2) and closely related with pradimicins in its structure and biological activity3~7).
Our previous studies demonstrated that benanomicin A inhibited growth of a wide range of pathogenic fungi8), and that either intravenous or subcutaneous doses of it were effective in protecting mice lethally infected with Candida albicans, Cryptococcus neoformans and Aspergillus fumigatus from death, while the antibiotic was DEC. 1997 favorably tolerated by experimental animals9). It was also found that benanomicin A had a selective affinity to yeast and other fungal cells, particularly cell surface mannans but not to bacteria or mammaliancells10). This may, at least, partly explain the selective toxicity of this antibiotic.
In the present paper we describes the results of studies performed to determine the mechanism of action of benanomicin A by which it exerts a fungicidal action toward susceptible yeasts.
Materials and Methods Compounds
Benanomicin Awas prepared in the Pharmaceutical supplemented with 20mM HEPES buffer (pH 6.4), 0.1 mMCaCl2 and 2% glucose. The cell suspension was dispensed into 1 5 ml-disposable tubes which received the indicated concentrations of benanomicin A. All tubes were incubated at 27°C under mild shaking. One-ml of sample was taken from each tube at 0, 10, 30 and 60 minutes of incubation and filtered through a Millipore filter. Potassium content in the nitrate was measured with an atomic absorption spectrophotometer (Hitachi Z-6100). The total cellular potassium content was determined using samples obtained after boiling the untreated control cell suspension at 95°C for 10 minutes with subsequent filtration. Percent of potassium leakage was calculated on the basis of the total cellular potassium incubated at 27°C on a shaker. Samples of 1ml were taken every 10 minutes, and mixed with 0.5ml of 3mM uranyl nitrate (pH 4.0) in an ice-cooled bath to terminate the reaction. The mixture was poured onto a glass fiber paper (Whatman GF/A) to collect the cells, which were then washed once with 3mMuranyl nitrate and twice with distilled water. The glass fiber papers were dried and measured for radioactivity in a scintillation counter.
Determination of the Effect of Osmotic Shock on Susceptibility to Benanomicin A Washedyeast cells suspended in YNBbroth supplemented with 1.2m sorbitol and Dulbecco's phosphate buffered saline (pH 7.5; Sigma) were incubated statically at room temperature for 1 hour with or without 100 /ig/ml of benanomicin A. Then the suspension was rapidly diluted with 10-fold volume of distilled water (for osmotic shock) or 1.2m sorbitol (for non-osmotic shock) at a cell concentration of 4 x 107 cells/ml. Both experimental cell suspensions were dispensed into test tubes with or without the indicated concentrations of benanomicin A and incubated at room temperature for 30 minutes. Viable counts were measuredas described above.
Measurement of Lytic Activity against Yeast Protoplasts and Erythrocytes
Saccharomyces protoplasts were prepared by the method reported10). Protoplasts were suspended in 1/15 m sodium phosphate buffer (pH 7.0) supplemented with 1.2m sorbitol and with or without 1% glucose at a concentration of 1 x 106 cells/ml. The protoplast suspension was dispensed into tubes which received the indicated concentration of benanomicin A and was incubated at 27°C. After 15, 30 and 60 minutes, a sample was taken from each tube and centrifuged at 2000rpm for 5 minutes to remove the supernatant. The amount of protein in the supernatant was determined using protein assay kit (Bio-Rad Laboratories). The total amount of soluble proteins in the protoplast was determined using the supernatant following bursting of the untreated control protoplasts by the addition of distilled water. Percent of lysis was calculated on the basis of the total cellular protein content. The experimental procedure to determine erythrocyte hemolysis was that reported10).
Determination of Glucose Release from Liposomes
Encapsulating Glucose
Presome PPG-I (phosphatidylcholine : cholesterol :
phosphatidyl-glycerol= 1 : 1 : 0.2; Nihon Seika Co.) was This indicated that benanomicin A-sensitivity of cultures decreased with increase in inoculum size or depended on the ratio of a number of target cells to drug molarity ratio, especially in the case where the inoculum size exceeded 106 cells/ml. Thus, this marked effect of initial cell concentration of cultures on the antifungal activity of benanomicin A was taken into consideration when the experiments were conducted using a cell suspension at a concentration of 107 cells/ml or higher. Next, we compared the effect of benanomicin A on the viability of growing cultures with that ofnon-growing cultures to examinewhether or not the benanomicinA sensitivity depends on the phase of growth of a culture.
As shown in Fig. 1 , when cells were incubated in a growth-supporting glucose-containing medium(YNBG broth), viable numbers were lowered by benanomicin A in a dose-dependent manner at concentrations above 5^g/ml. By contrast, in glucose-depleted medium (YNB broth), benanomicin A had no effect on viable cell counts at drug concentrations up to 20 fig/ml. These data suggest that benanomicin A exerts a fungicidal action toward Effect of Benanomicin A on Biosynthesis of Major Cellular Constituents in Yeast Cells The above result that benanomicin A appears to be active exclusively against growing or metabolically active yeast cell, led us to the possibility that the antibiotic acts preferentially on someanabolic metabolismof cellular constituents of vital importance, such as the biosynthesis of protein, RNA, DNA, lipid or cell wall polysaccharides (glucan, chitin and mannan) in this yeast. Table 2 shows the results of experiments in which the effect of the antibiotic on the incorporation of several radioactive precursors into their respective cellular fractions was examined. With 80/xg/ml of benanomicin A (approx. 1 MICequivalent), the extent of inhibition of incorporation of all species of precursors employed was maximally 55%, suggesting that none of the anabolic metabolisms of major cellular constituents is preferably sensitive to benanomicin A. 
Effect of Benanomicin A on Influx of [14C]Deoxy-glucose in Yeast Cells
To learn whether benanomicin A affects permeability of some essential substrate such as glucose in yeasts, we studied the effect of the antibiotic on influx of 6-deoxyglucose because it is an unmetabolizable analog of glucose. Yeast cells suspended in YNBGbroth containing 1 mMof glucose and 1 mM[14C]6-deoxy-glucose were incubated with the indicated concentration of benanomicin A. As shown in Fig. 3 , the radioactive substrate was taken up in the untreated control cells at a steady rate for 40 minutes of the incubation period, whereas in the presence of benanomicin A at concentrations of 20 and 80^g/ml (1/4 and 1 MIC equivalent, respectively), the level of 6-deoxy-glucose uptake was 50%lower 20 minutes after the onset of incubation, at which time the uptake was almost completely leveled off.
Effect of Benanomicin A on Resistance to Osmotic Shock of Yeast Cells Since we found earlier that benanomicin A has a selective affinity for mannan10), we postulated that through this interaction the antibiotic alters the physicochemical properties of cell walls and/or cell membranes.
Thus experiments were conducted to see whether or not benanomicin A has an effect on yeast cell resistance to Table 3 , the viability of yeast cells was scarcely or only slightly affected when they were subjected to either osmotic shock or benanomicin A-treatment, but when benanomicin A-treated yeast cells were subjected to osmotic shock, viability was markedly reduced.
Lytic Effect of Benanomicin A on Yeast Protoplasts The membrane-active property of benanomicin A was more directly examined by measuring the lytic effect of the antibiotic on yeast protoplasts suspended in phosphate buffered 0.8 M-sorbitol as an osmotic stabilizer. As shown in Fig. 4 , in the presence of glucose, yeast protoplasts suspended in glucose-supplemented medium were susceptible to benanomicin A; when the yeast protoplasts were exposed to 20 and 80/ig/ml of benanomicin A (1/4 and 1 MIC equivalent, respectively), approx. 20 and 60%lysis, respectively, was observed in 30 to 60 minutes. The yeast protoplasts suspended in glucose-depleted medium, however, were far less susceptible to benanomicin A despite there being no significant difference in the amount of the antibiotic bound to the protoplasts between these two suspensions. Sheep erythrocytes lacking in affinity for benanomicin A were highly resistant to its lytic action irrespective of the presence or absence of glucose (data not shown). Liposomes prepared from phosphatidylcholine : cholesterol : phosphatidylglycerol= 1 : 1 : 0.2 with encapsulating glucose were incubated at 25°C for 60 minutes with the indicated drugs.
Effect of Benanomicin A on Liposomes
To learn whether the membrane-active property of benanomicin A is due to its direct interaction with some lipid components of the yeast cell membraneresulting in membranedamage or disruption, the effect of the antibiotic on glucose-trapped liposomes prepared from phospholipids and cholesterol was examined. As shown in Table 4 , while tioconazole (80 jUg/ml) or amphotericin B (40/^g/ml) which are knownto have selective affinity for phospholipids and sterols, respectively24'25^induced release of large amounts of trapped glucose from liposomes, benanomicin A up to a concentration of 320/ig/ml did not induce substantial glucose release, indicating that the liposomes were basically insusceptible to the antibiotic. See Materials and Methods for assay conditions.
Effect of Benanomicin.A on the Activities of ATPase from Yeast Cells
In addition to the above-mentioned data, the selective affinity of benanomicin A for mannansuggests to us that some mannoproteins localized on the cell membrane may be the target of benanomicin A action. To test this possibility, yeast cell membrane H+-ATPase (P-ATPase) was chosen as one such mannoprotein and the benanomicin A susceptibility of this enzyme was compared with that of vacuolar membraneH+-ATPase (V-ATPase) and mitochondrial H+-ATPase (Fx-ATPase) from yeast, both of which are known to be mannan-free enzymes. As shown in Table 5 , 20 /ig/ml of benanomicin A inhibited P-ATPase activity by approx.
50%, whereas only slightly or not at all inhibited V-ATPase activity or Fx-ATPase activity. In addition to such physico-chemical and mechanical Different from P-ATPase, both FrATPase and V-ATPase are known to lack mannanmoiety in their molecule. The present study, comparing the effect of benanomicin A on these three types of H+-ATPase from yeasts, showed that PATPase was preferentially susceptible to the antibiotic. However, because the P-ATPase inhibitory activity of benanomicin A appears to be much lower that of omeprazole, which is known to be a potent fungicidal and to selectively inhibit the P-ATPase activity31}, the antifungal activity of the antibiotic likely is not solely based on its inhibition of P-ATPase activity. All of the results obtained in the present study suggest to us that detrimental changes in the structure and/or function of cell membrane induced by benanomicin A, probably resulting from its interaction with not only "sparking" mannoproteins such as P-ATPase but also "bulk" mannoproteins of the cell membrane, would be primarily involved in the antifungal action of the antibiotic. The mechanism of such membraneaction of benanomicin A, although not clarified on the molecular level, seems to be unique and distinct from that of any existing antifungal agents so far known. Considering this and other 
